Biomarkers

João Pedro Ferrari-Souza1, Guilherme Povala2, Nesrine Rahmouni3

  • 1Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.

Abstract

Insights

Microglial activation links amyloid-beta (Aβ) pathology to astrocyte reactivity in Alzheimer

Area of Science:

  • Neuroscience
  • Neuroimmunology
  • Biomarker Research

Background:

  • Glial cells, including astrocytes and microglia, are key players in Alzheimer's disease (AD) neuroinflammation.
  • Microglia activation's role in modulating astrocyte reactivity in response to amyloid-beta (Aβ) in the human brain remains unclear.

Purpose of the Study:

  • To investigate how microglia activation influences the effects of Aβ pathology on astrocyte reactivity in individuals across the aging and AD spectrum.
  • To test the hypothesis that microglia mediate the relationship between Aβ and astrocyte reactivity in the living AD brain.

Main Methods:

  • Utilized data from the Translational Biomarkers in Aging and Dementia (TRIAD) study, including positron emission tomography (PET) imaging and fluid biomarkers.
  • Assessed microglial activation (TSPO PET, CSF sTREM2), Aβ plaques (PET), reactive astrocytes (plasma GFAP), and tau pathology (p-tau217, tau PET).
  • Analyzed data from cognitively unimpaired, mild cognitive impairment, and AD dementia participants.

Main Results:

  • Aβ pathology was associated with astrocyte reactivity only when microglial activation was elevated, confirming microglia's mediating role.
  • Both TSPO PET and CSF sTREM2 confirmed microglial activation's influence on Aβ-induced astrocyte reactivity.
  • Microglial activation and astrocyte reactivity were jointly linked to tau phosphorylation and aggregation.
  • The Aβ-induced, microglia-dependent astrocyte reactivity contributed to cognitive impairment via tau pathology.

Conclusions:

  • Microglial activation is a critical link between Aβ and astrocyte reactivity in the Alzheimer's disease brain.
  • Findings elucidate the complex microglia-astrocyte crosstalk in AD, suggesting potential glia-targeting therapeutic strategies.